RAC1 and B-cell chronic lymphocytic leukemia: It is worth mentioning that cirmtuzumab was also shown to inhibit Wnt5a-induced Rac1 activation in CLL in combination with ibrutinib, revealing a promising role for the anti-ROR1 mAb in blocking alternative survival signaling cascades, such as the BCR-signaling [126].